Ashvattha Therapeutics Appoints Industry Veteran George G. Montgomery to its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors. “We are honored to have George join our Boar